版本:
中国

BRIEF-Cytrx says FDA agreement on regulatory pathway for Aldoxorubicin

April 19 Cytrx Corp:

* Cytrx announces FDA agreement on regulatory pathway to approval for Aldoxorubicin in soft tissue sarcomas

* Development program can support approval, no new studies requested

* Cytrx is under confidentiality agreements with a number of companies for a commercial partnership for marketing of Aldoxorubicin

* NDA submission by Cytrx being prepared

* Goal is to submit a rolling NDA to FDA for soft tissue sarcomas in last quarter of 2017

* Proposed product label would include treatment of soft tissue sarcomas

* Is under confidentiality agreements with a number of companies for a commercial partnership for marketing of Aldoxorubicin

* Also plans to discuss with European Medicines Agency a path to filing a marketing authorization application

* Commercial launch of Aldoxorubicin is still projected for 2018 in United States Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐